Biotest Aktiengesellschaft (XETRA:BIO3) — Market Cap & Net Worth
Market Cap & Net Worth: Biotest Aktiengesellschaft (BIO3)
Biotest Aktiengesellschaft (XETRA:BIO3) has a market capitalization of $656.94 Million (€561.91 Million) as of May 3, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #11147 globally and #1254 in its home market, demonstrating a -5.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biotest Aktiengesellschaft's stock price €28.40 by its total outstanding shares 19785700 (19.79 Million). Analyse cash efficiency ratio of Biotest Aktiengesellschaft to see how efficiently the company converts income to cash.
Biotest Aktiengesellschaft Market Cap History: 2015 to 2025
Biotest Aktiengesellschaft's market capitalization history from 2015 to 2025. Data shows growth from $350.89 Million to $656.94 Million (4.47% CAGR).
Biotest Aktiengesellschaft Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biotest Aktiengesellschaft's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.86x
Biotest Aktiengesellschaft's market cap is 0.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
23.66x
Biotest Aktiengesellschaft's market cap is 23.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $350.89 Million | $589.60 Million | -$82.50 Million | 0.60x | N/A |
| 2016 | $305.91 Million | $553.10 Million | -$45.80 Million | 0.55x | N/A |
| 2017 | $462.91 Million | $378.10 Million | -$3.50 Million | 1.22x | N/A |
| 2018 | $539.42 Million | $400.30 Million | $181.70 Million | 1.35x | 2.97x |
| 2019 | $471.41 Million | $419.10 Million | -$4.70 Million | 1.12x | N/A |
| 2020 | $647.44 Million | $484.20 Million | -$31.40 Million | 1.34x | N/A |
| 2021 | $890.59 Million | $515.60 Million | -$63.40 Million | 1.73x | N/A |
| 2022 | $785.35 Million | $516.10 Million | -$31.70 Million | 1.52x | N/A |
| 2023 | $716.05 Million | $684.60 Million | $127.00 Million | 1.05x | 5.64x |
| 2024 | $624.55 Million | $726.20 Million | $26.40 Million | 0.86x | 23.66x |
Competitor Companies of BIO3 by Market Capitalization
Companies near Biotest Aktiengesellschaft in the global market cap rankings as of May 3, 2026.
Key companies related to Biotest Aktiengesellschaft by market ranking:
- PRINC.PR.EQ.HLDGS EO-001 (F:PEYA): Ranked #11138 globally with a market cap of $658.08 Million USD ( €562.89 Million EUR).
- BCI Minerals Limited (F:BC3): Ranked #11139 globally with a market cap of $658.02 Million USD ( €562.84 Million EUR).
- Mensch und Maschine Software SE (F:MUM): Ranked #11148 globally with a market cap of $656.90 Million USD ( €561.88 Million EUR).
- Chapters Group AG (XETRA:CHG): Ranked #11149 globally with a market cap of $656.80 Million USD ( €561.80 Million EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #11138 | PRINC.PR.EQ.HLDGS EO-001 | F:PEYA | $658.08 Million | €8.14 |
| #11139 | BCI Minerals Limited | F:BC3 | $658.02 Million | €0.22 |
| #11148 | Mensch und Maschine Software SE | F:MUM | $656.90 Million | €39.90 |
| #11149 | Chapters Group AG | XETRA:CHG | $656.80 Million | €30.20 |
Biotest Aktiengesellschaft Historical Marketcap From 2015 to 2025
Between 2015 and today, Biotest Aktiengesellschaft's market cap moved from $350.89 Million to $ 656.94 Million, with a yearly change of 4.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €656.94 Million | +5.19% |
| 2024 | €624.55 Million | -12.78% |
| 2023 | €716.05 Million | -8.82% |
| 2022 | €785.35 Million | -11.82% |
| 2021 | €890.59 Million | +37.56% |
| 2020 | €647.44 Million | +37.34% |
| 2019 | €471.41 Million | -12.61% |
| 2018 | €539.42 Million | +16.53% |
| 2017 | €462.91 Million | +51.32% |
| 2016 | €305.91 Million | -12.82% |
| 2015 | €350.89 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Biotest Aktiengesellschaft was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $656.94 Million USD |
| MoneyControl | $656.94 Million USD |
| MarketWatch | $656.94 Million USD |
| marketcap.company | $656.94 Million USD |
| Reuters | $656.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more